Miami, Fl – January 29, 2010 –Dual enrollment occurs when a human research subject enrolls in overlapping clinical trials without meeting protocol required washout periods. Currently, researchers have no way to verify subject washout periods and are forced to rely on a subject’s word to evaluate this component of subject eligibility.
Because some subjects participate in early phase research as a way to earn money, researchers are concerned that an incentive exists for subjects to misrepresent the last time they received a study dose in order to become enrolled in an upcoming clinical trial.
In 2009, several unaffiliated clinical research institutions in South Florida joined together to create a subject registry called clinicalRSVP that proactively safeguards against dual enrollment. A neutral administrator was commissioned, and a Web-centric database capable of tracking subjects and their dose dates was created, resulting in a way for investigators to check if a subject was recently dosed before enrolling them to an upcoming clinical trial.
Since the launch of this network in October 2009, the 5 participating sites have registered over 1,500 subjects. As a result, these sites were able, on multiple occasions, to identify recently dosed subjects attempting to screen for an upcoming trial and fairly exclude them from participating. The five sites continue to use clinicalRSVP as a way to ensure trial accuracy and encourage other sites to join as a way to increase the effectiveness of the network.
ClinicalRSVP was developed and is administered by Independent Data Integrator (IDI), a company specializing in clinical database management. IDI worked closely with the South Florida sites, along with various legal advisors and institutional review board (IRB) experts to develop the clinicalRSVP program. Plans are underway to introduce additional networks in the Midwest and Northeast.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.